Caprolactam Chem

What does Caprolactam Chem do?

Caprolactam Chemicals Ltd is a micro-cap company in the commodity chemicals industry, incorporated in 1988, with net sales of 2 Cr and a market cap of Rs 20 Cr as of March 2025. The company has faced financial challenges, reporting no net profit and a negative return on equity of -13.35%.

Overview:<BR>Caprolactam Chemicals Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in November 1988 and was registered as a sick company by the Board of Industrial and Finance Reconstruction (BIFR) in 2001. As of the latest quarter reported, which is March 2025, the company has net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 20 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 13 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.33 <BR>Return on Equity: -13.35% <BR>Price to Book: 3.67<BR><BR>Contact Details:<BR>Address: B/31 MIDC Industrial Area, Taluka - Mahad Raigad Maharashtra : 402302 <BR>Tel: 91-2145-233427 <BR>Email: caprolactumcl@gmail.com <BR>Website: http://www.caprolactam.co.in

Who are in the management team of Caprolactam Chem?

As of March 2022, the management team of Caprolactam Chem includes Z S Bhanushali (Chairperson & Managing Director), S S Bhanushali (Whole Time Director & CFO), V P Adagale, R P Mange, and Poonam Bhavin Bhanushali (all Independent Directors), along with Dolly Dipesh Shah (Company Secretary & Compliance Officer).

As of March 2022, the management team of Caprolactam Chem includes the following individuals:<BR><BR>1. Z S Bhanushali - Chairperson & Managing Director<BR>2. S S Bhanushali - Whole Time Director & Chief Financial Officer<BR>3. V P Adagale - Independent Director<BR>4. R P Mange - Independent Director<BR>5. Poonam Bhavin Bhanushali - Independent Director<BR>6. Dolly Dipesh Shah - Company Secretary & Compliance Officer<BR><BR>These members play key roles in the governance and operational management of the company.

Has Caprolactam Chem declared dividend?

No Dividend History Available

Who are the peers of the Caprolactam Chem?

Caprolactam Chem's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries. In terms of returns, India Glycols leads with 150.46% over one year, while Caprolactam Chem has the lowest at -33.11%.

Peers: The peers of Caprolactam Chem are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals, India Glycols, Emmessar Biotech, and Link Pharma Chem, while Below Average management risk is noted for Fischer Medical, Caprolactam Chem, Vivid Global, and Kuwer Industries. Growth ratings show that Excellent capital structure is at GHCL, while Average capital structure is found at Tata Chemicals and the rest. Below Average capital structure is noted for Chemplast Sanmar, India Glycols, Fischer Medical, Caprolactam Chem, Emmessar Biotech, Link Pharma Chem, Vivid Global, and Kuwer Industries.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.46%, while Caprolactam Chem has the lowest at -33.11%. Caprolactam Chem's return is significantly lower than all peers. Additionally, the six-month return is negative for Tata Chemicals, Chemplast Sanmar, Caprolactam Chem, Emmessar Biotech, and Vivid Global.

What is the technical trend for Caprolactam Chem?

As of June 6, 2025, Caprolactam Chem's technical trend is mildly bearish, supported by bearish MACD and moving averages, despite a mildly bullish KST signal on the weekly chart.

As of 6 June 2025, the technical trend for Caprolactam Chem has changed from bearish to mildly bearish. The weekly MACD remains bearish, and the monthly MACD is also bearish, indicating ongoing downward momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the negative outlook. Daily moving averages are bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly chart, but the monthly remains bearish, indicating mixed signals. Dow Theory indicates a mildly bearish stance on the weekly chart, with no clear trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages.

Who are the top shareholders of the Caprolactam Chem?

The top shareholders of Caprolactam Chem include Siddharth Shankarlal Bhanushali with 22.98%, and individual investors who hold 43.84% of the shares. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Caprolactam Chem primarily consist of its promoters, with Siddharth Shankarlal Bhanushali holding the largest share at 22.98%. Additionally, individual investors collectively hold 43.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

How big is Caprolactam Chem?

As of 24th July, Caprolactam Chemicals Ltd has a market capitalization of 20.00 Cr and reported Net Sales of 6.73 Cr with a Net Profit loss of 0.71 Cr in the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 5.55 Cr and Total Assets of 11.65 Cr.

As of 24th July, Caprolactam Chemicals Ltd has a market capitalization of 20.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 6.73 Cr. However, it experienced a Net Profit loss of 0.71 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 5.55 Cr and Total Assets of 11.65 Cr.

When is the next results date for Caprolactam Chem?

Caprolactam Chem will announce its results on 14 August 2025.

Caprolactam Chem will declare its results on 14 August 2025.

Are Caprolactam Chem latest results good or bad?

Caprolactam Chemicals' latest results show strong year-on-year sales growth of 59.51% and record profits, but declining liquidity and slower debt collection present challenges, indicating a mixed performance overall.

Caprolactam Chemicals has shown a mixed performance in its latest results for the quarter ending June 2025. On the positive side, the company reported a significant year-on-year growth in net sales of 59.51%, reaching Rs 6.46 crore for the nine-month period. Additionally, both profit before tax and profit after tax reached their highest levels in the last five quarters, with earnings per share increasing to Rs 0.78.<BR><BR>However, there are notable challenges as well. The company's cash and cash equivalents have decreased to Rs 0.08 crore, indicating a decline in short-term liquidity. Furthermore, the debtors turnover ratio has dropped to 2.39 times, suggesting a slowdown in the collection of debts.<BR><BR>Overall, while the growth in sales and profits is encouraging, the liquidity issues and slower debt collection raise concerns. Thus, the results can be seen as a mix of good and bad, highlighting both progress and challenges for Caprolactam Chemicals.

How has been the historical performance of Caprolactam Chem?

Caprolactam Chem has experienced significant declines in net sales and profitability, with net sales dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025, and profit after tax turning negative at -0.71 Cr. The company faces ongoing financial difficulties, reflected in increased liabilities and stagnant cash flow.

Answer:<BR>The historical performance of Caprolactam Chem has shown significant fluctuations over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Caprolactam Chem's net sales peaked at 9.84 Cr in March 2023 but have since declined to 6.74 Cr by March 2025. The total operating income followed a similar trend, dropping from 9.84 Cr in March 2023 to 6.74 Cr in March 2025. The company faced challenges with operating profit, which reached a high of 4.67 Cr in March 2023 but fell to 1.54 Cr by March 2025. Profit before tax also turned negative in March 2025 at -0.68 Cr, contrasting with a profit of 2.97 Cr in March 2023. Consequently, profit after tax reflected a loss of -0.71 Cr in March 2025, down from a profit of 2.55 Cr in March 2023. The company's total liabilities increased from 11.52 Cr in March 2023 to 14.28 Cr in March 2025, while total assets rose slightly from 11.52 Cr to 14.28 Cr in the same period. Cash flow from operating activities remained stagnant, with no cash inflow reported in March 2025, indicating ongoing financial difficulties. Overall, Caprolactam Chem has experienced a decline in sales and profitability, leading to a challenging financial position in recent years.

Should I buy, sell or hold Caprolactam Chem?

Is Caprolactam Chem overvalued or undervalued?

As of November 28, 2025, Caprolactam Chem is considered overvalued with a high PE ratio of 2771.50 and other metrics significantly above industry norms, making it a less prudent investment despite a recent 20.14% stock return.

As of 28 November 2025, the valuation grade for Caprolactam Chem has moved from fair to expensive, indicating a shift in perceived value. The company is currently overvalued based on its high PE ratio of 2771.50, a price to book value of 5.21, and an EV to EBITDA of 15.28, which are significantly higher than industry norms. <BR><BR>In comparison, peers such as Sun Pharma have a PE ratio of 38.03 and an EV to EBITDA of 25.17, while Cipla, which is considered attractive, has a PE ratio of 22.71 and an EV to EBITDA of 16.07. The stark contrast in these ratios suggests that Caprolactam Chem is not only overvalued relative to its peers but also lacks the financial performance metrics that would justify such a high valuation. Despite recent strong stock performance, with a one-year return of 20.14% compared to the Sensex's 8.43%, the underlying valuation metrics indicate that the stock is not a prudent investment at its current price.

Why is Caprolactam Chemicals Ltd falling/rising?

As of 11-Mar, Caprolactam Chemicals Ltd's stock price is at 62.27, down 15.14%. The recent decline is due to erratic trading patterns, decreased delivery volume, and a significant underperformance compared to the Sensex, indicating a lack of investor confidence.

As of 11-Mar, Caprolactam Chemicals Ltd's stock price is falling, currently at 62.27, which reflects a change of -11.11 (-15.14%). This decline can be attributed to several factors observed in the recent trading activity. Over the past week, the stock has decreased by 19.38%, significantly underperforming the Sensex, which only fell by 2.85%. <BR><BR>Additionally, the stock has shown erratic trading patterns, having not traded on 5 out of the last 20 days, indicating a lack of consistent investor interest. The wide trading range of Rs 6.54 suggests volatility, but the weighted average price indicates that more volume has been traded closer to the lower price point. Furthermore, the stock's delivery volume has drastically decreased, with a reported delivery volume of 1 on February 16, which is a staggering 99.88% drop compared to the 5-day average. <BR><BR>While the stock has performed well over longer periods, such as a 1-year increase of 27.11% and a 5-year increase of 216.09%, the recent trends in trading volume and price movements suggest a current lack of confidence among investors, contributing to the stock's decline.

Why is Caprolactam Chemicals Ltd falling/rising?

As of 12-Mar, Caprolactam Chemicals Ltd's stock price is falling to Rs 59.21, reflecting a 4.91% decrease. The stock has underperformed with a 19.31% drop over the past month, driven by weak fundamentals and negative market sentiment despite increased investor participation.

As of 12-Mar, Caprolactam Chemicals Ltd's stock price is falling, currently at Rs 59.21, which reflects a decrease of Rs 3.06 or 4.91%. This decline is part of a broader trend, as the stock has underperformed significantly, with a 19.31% drop over the past month and consecutive losses for the last two days. The stock's performance today has also lagged behind its sector by 4.75%.<BR><BR>Several factors contribute to this downward movement. The stock has shown erratic trading patterns, having not traded on four days out of the last twenty, and it reached an intraday low of Rs 59.21. Additionally, while there has been a rise in investor participation, with delivery volume increasing by 284.64% against the five-day average, the overall sentiment remains negative due to weak long-term fundamentals. The company's Return on Capital Employed (ROCE) is low at 7.92%, indicating poor long-term growth potential, and its ability to service debt is concerning, as evidenced by a weak EBIT to Interest ratio of 0.86.<BR><BR>Moreover, despite a strong one-year return of 43.33%, the company's profits have only risen by 28%, leading to a high PEG ratio of 26.3, suggesting that the stock may be overvalued compared to its earnings growth. This combination of poor financial metrics and recent performance trends has led to the stock's current decline.

Which are the latest news on Caprolactam Chem?